Action CYTO ALTAMIRA THERAPEUTICS LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Altamira Therapeutics Ltd.

Actions

CYTO

BMG0360L1349

Cours en clôture Nasdaq
Autres places de cotation
 00:00:00 15/05/2024 		Varia. 5j. Varia. 1 janv.
1,53 USD +6,25% Graphique intraday de Altamira Therapeutics Ltd. +4,08% -56,03%
01/05 Altamira Therapeutics Ltd. annonce le dépôt d'une demande de brevet provisoire pour des nanoparticules OligoPhore avec siRNA ciblant la protéine p65 dans le traitement du cancer et de l'inflammation CI
24/04 Altamira Therapeutics Ltd. annonce la publication des résultats positifs de l'étude Bentrio dans la rhinite allergique saisonnière dans un journal de référence CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Altamira Therapeutics : Notice of the Annual General Meeting of Shareholders of Altamira Therapeutics Ltd. (the “Company”) to be held on May 16, 2024 - Form 6-K
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
Altamira Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
Sector Update: Health Care Stocks Decline Late Afternoon
Top Midday Gainers
Sector Update: Health Care Stocks Softer in Afternoon Trading
Altamira, Univercells Partner to Test mRNA Vaccine Delivery; Shares Surge
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
Altamira Therapeutics Ltd. Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
Altamira Therapeutics? Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
Altamira Files Second Provisional Patent Application in Cancer Treatment; Shares Rise
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CYTO
  4. Actualités Altamira Therapeutics Ltd.
  5. Autres langues